<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the effectiveness and toxicity of the regimen combined homoharringtonine, low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> with G-CSF or GM-CSF (HAG regimen) in treating patients with relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, geriatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and advanced <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Forty patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with HAG regimen for remission induction and consolidation therapy </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them were followed up till April 2006 </plain></SENT>
<SENT sid="3" pm="."><plain>Results 20 of them (50%) achieved complete remission (CR), including 46.2% patients with relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 60% elderly patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who were either untreated or treated with only one course of induction therapy previously, and 66.7% patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>After a follow-up of 6- 47 (median 23) months from the date of remission, the median times of relapse-free survival and overall survival were (7.0 +/- 1.1) and (28 +/- 12.3) months, respectively </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">Myelosuppression</z:e> was the most significant toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>The incidences of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and <z:mp ids='MP_0001914'>hemorrhage</z:mp> which exceed grade II were 43.8% and 37.5%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Non-hematologic adverse effects were minimal </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The HAG regimen presented effective and well-tolerated </plain></SENT>
<SENT sid="9" pm="."><plain>It seems promising for the treatment of relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, geriatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>